Daxor announces new data on benefits of BVA

Daxor Corporation announces new data from Duke University Medical Center validating the benefits of blood volume analysis, BVA, in optimizing individualized therapy for heart failure patients with impaired renal function. Data were presented on 259 patients from three centers at the Technology and Heart Failure Therapeutics Conference, THT, which brought together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024. Veraprapas Kittipibul M.D., lead investigator of the study concluded that: Heterogeneity in volume exists across renal function which can only be accurately measured with BVA. Patients with large volume expansion had worsening renal function, showing the urgent need for care. Pressure-volume correlation is consistently weak across renal function, showing that BVA is the right tool. Anemia, especially dilutional anemia, is more prevalent in worse renal function, also detectable by BVA. “The cornerstone of heart failure care is volume management, and an accurate diagnosis of this is crucial, especially in patients at significant risk for kidney disease,” said Michael Feldschuh, CEO and President of Daxor. “Our BVA technology provides clinicians with 98% accurate, actionable data to optimize treatment plans and individualize care, improving outcomes while reducing duration and cost of care.”